Rein Therapeutics Inc. (RNTX)
| Market Cap | 37.39M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -62.88M |
| Shares Out | 21.99M |
| EPS (ttm) | -3.51 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 7,161 |
| Open | 1.650 |
| Previous Close | 1.650 |
| Day's Range | 1.650 - 1.650 |
| 52-Week Range | 1.350 - 7.420 |
| Beta | 2.12 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Apr 7, 2025 |
About RNTX
Rein Therapeutics Inc., a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. The company’s lead product candidate is LTI-03, a peptide, which is in Phase 1b clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF). Its second product candidate is LTI-01, a proenzyme that has completed Phase 1b and Phase 2a clinical trials in LPE patients for the treatment of loculated pleural effusion. The company’s pipeline also includes pre... [Read more]
Financial Performance
Financial StatementsNews
Rein Therapeutics Announces a Publication in Biomedicines on the Immunomodulatory and Anti-fibrotic Properties of a Caveolin-1-Related Peptide in IPF and PASC-F
Manuscript highlights the effects of caveolin scaffolding domain peptide LTI-2355 on myeloid cell activity in Idiopathic Pulmonary Fibrosis (IPF) and Post-Acute Sequelae of COVID Fibrosis (PASC-F) AUS...
Rein Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
Rein advanced the clinical development of its lead asset, LTI-03, and aims to initiate a Phase 2 trial for the treatment of idiopathic pulmonary fibrosis (IPF) in the first half of 2025 Positive topli...